Glenmark Pharmaceuticals Ltd - Share Price
GLENMARK
Glenmark Pharmaceuticals LtdFinancials
Glenmark Pharmaceuticals LtdNews & Updates
Glenmark Pharma gets ANDA nod for Clindamycin Phosphate Foam; Stock gains
Sep 21,2021 10:05 AM
Clindamycin Phosphate Foam is the generic version of Evoclin1 Foam, 1%, of Mylan Pharmaceuticals Inc.
Glenmark Pharma buys back FCC Bonds $1M at repurchase rate of $1.2M Sep 16,2021
Glenmark Pharmaceuticals buybacks USD 1 mn FCCBs Sep 15,2021
Glenmark concludes post marketing surveillance study on Favipiravir in India; Stock gains 1% Sep 15,2021
Glenmark Pharmaceuticals to conduct AGM Aug 25,2021
Glenmark Pharma Aug 14,2021
Meeting Type
Meeting Date
| Resolution Type | Description Of Resolution | IiAS Recommendation |
|---|
Peer Comparison
| Name | LTP | PE | Mar Cap | NP Qtr | Div. Yld | Sales Qtr | BV |
|---|
Figures of Market Capital(Mar Cap), Quaterly Net Profit(NP Qtr) and Quaterly Sales(Sales Qtr) are in Cr.
Glenmark Pharmaceuticals LtdSummary & Reports
Glenmark Pharmaceuticals Ltd was incorporated in November 18th, 1977. The company is actively involved in the discovery of new molecules both NCEs (new chemical entity) and NBEs (new biological entity). It is engaged in the business of development, manufacture and marketing of pharmaceutical products both formulation and active pharmaceuticals ingredients to regulated and semi-regulated markets. The company has several molecules in var... More
Registered Office
B/2 Mahalaxmi Chambers,22 Bhulabhai Desai Road,Mumbai, Maharashtra,400026
Tell. : +91-22-40189999
Website : http://www.glenmarkpharma.com
Email : complianceofficer@glenmarkpharma.com
Registrar Office
Karvy Selenium Tow-B, Nanakramguda, Hyderabad-500032 INDIA
Tell. : +91-40-67162222
Website : www.kfintech.com
Email : einward.ris@kfintech.com
Reports by glenmark-pharmaceuticals-ltd-share-price
Latest Release by glenmark-pharmaceuticals-ltd-share-price
Result Express
Sep 28, 2021 07:54 AM
The company’s consolidated revenue stood at Rs2,581.33cr, up 14.39% yoy and 19.2% qoq.
Shareholding Snapshot
Loading ...
| Jun - 2021 | |
|---|---|
| Promoter | - |
| Foreign | 0.00% |
| Indian | 46.63% |
| Total Promoter | 46.63% |
| Non Promoter | - |
| Institutions | 36.55% |
| Non-Institutions | 16.82% |
| Total Non-Promoter | 53.37% |
| Custodian | 0.00% |
| Total | 100% |
Corporate Action
Purpose
Dividend
Annc. Date
28 May 2021
Effective. Date
08 Sep 2021
Divi. Type
Final
Divi.(%)
250
Divi. Amt.
2.5
Glenmark Pharmaceuticals Ltd has informed BSE that the Board of Directors of the Company at its meet... More
Purpose
Board Meeting
Exp. Date
13 Aug 2021
Annc. Date
05 Aug 2021
Quarterly ResultsGLENMARK PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Dire... More
